SCHEMBL18173003

SCHEMBL18173003

CC(C)(C)OC(=O)N(Cc1ccccc1CBr)C(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 2/20 0.43
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C19 P33261 1/20 0.37
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
NCOR2 Q9Y618 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CTSS P25774 2/20 0.36
CTSK P43235 1/20 0.36
ITGA4 P13612 1/20 0.35
ITGB7 P26010 1/20 0.35
SSTR4 P31391 1/20 0.34
HTR2C P28335 1/20 0.34
SLC6A4 P31645 1/20 0.34
NR1D1 P20393 1/20 0.34
GRM2 Q14416 1/20 0.34
RIPK1 Q13546 1/20 0.33
CTSL P07711 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21089291 0.86 HTR2C (0.43) AKT1CYP1A2CYP2D6CYP2C19CTSS
SCHEMBL1845414 0.82 AKR1B1 (0.43) AKT1HDAC3HDAC1HDAC2NCOR2
SCHEMBL18172845 0.82 TSHR (0.40) AKT1
SCHEMBL31490982 0.81 GRM2 (0.44) AKT1HDAC3HDAC1HDAC2NCOR2
SCHEMBL13656744 0.80 NR1D1 (0.40) AKT1CYP1A2CYP2D6CYP2C19HDAC3
SCHEMBL19153416 0.79 AKT1 (0.43) AKT1HDAC3HDAC1HDAC2NCOR2
SCHEMBL8635430 0.78 AKT1 (0.44) AKT1HDAC3HDAC1HDAC2NCOR2
SCHEMBL3819098 0.78 AKT1 (0.52) AKT1HDAC3HDAC1HDAC2NCOR2
SCHEMBL15760930 0.77 SSTR4 (0.43) AKT1CYP1A2SSTR4GRM2
SCHEMBL4396244 0.77 GRM2 (0.41) AKT1CYP1A2CYP2D6CYP2C19HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3286172-B1 LSD1 INHIBITORS AND USES THEREOF CONSTELLATION PHARMACEUTICALS INC (US) 2019-06-12 EP disclosed
EP-3286172-B1 LSD1 INHIBITORS AND USES THEREOF CONSTELLATION PHARMACEUTICALS INC (US) 2019-06-12 EP disclosed
US-20180290976-A1 LSD1 INHIBITORS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. 2018-10-11 US disclosed
EP-3286172-A1 LSD1 INHIBITORS AND USES THEREOF Constellation Pharmaceuticals, Inc. (US) 2018-02-28 EP disclosed
WO-2016172496-A1 LSD1 INHIBITORS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. (US) 2016-10-27 WO disclosed
WO-2016172496-A1 LSD1 INHIBITORS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. (US) 2016-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180290976-A1 LSD1 INHIBITORS AND USES THEREOF KDM1B, KDM1A, KDM2A AKT1 2612/4885CYP1A2 378/4885CYP2D6 1305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.